NewGenIvf Group Announces Update On Proposed Reverse Merger With COVIRIX Medical; Due Diligence Progressing, Anticipated Completion By End Of August 2024; COVIRIX Engages U.S. University For Antiviral Drug Study, Holds 80K Zucoins In Treasury
NewGenIvf Group Announces Update On Proposed Reverse Merger With COVIRIX Medical; Due Diligence Progressing, Anticipated Completion By End Of August 2024; COVIRIX Engages U.S. University For Antiviral Drug Study, Holds 80K Zucoins In Treasury
NewGenIvf集團宣佈關於與COVIRIX醫療的倒向合併計劃的最新消息；盡職調查正在進行中，預計在2024年8月底完成；COVIRIX聘請美國大學進行抗病毒藥物研究，儲備8萬Zucoins。
NewGenIvf Group Announces Update On Proposed Reverse Merger With COVIRIX Medical; Due Diligence Progressing, Anticipated Completion By End Of August 2024; COVIRIX Engages U.S. University For Antiviral Drug Study, Holds 80K Zucoins In Treasury
NewGenIvf集團宣佈關於與COVIRIX醫療的倒向合併計劃的最新消息；盡職調查正在進行中，預計在2024年8月底完成；COVIRIX聘請美國大學進行抗病毒藥物研究，儲備8萬Zucoins。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。